William Blair stays Outperform on Eupraxia Pharmaceuticals (EPRX) as data shows 'robust response'
Tweet Send to a Friend
William Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating on Eupraxia Pharmaceuticals (NASDAQ: EPRX)The analyst commented, "Top-line 36-week data from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
